101 related articles for article (PubMed ID: 698922)
21. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E
Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813
[TBL] [Abstract][Full Text] [Related]
22. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
23. Combination of N,N',N"-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo.
Teicher BA; Holden SA; Cucchi CA; Cathcart KN; Korbut TT; Flatow JL; Frei E
Cancer Res; 1988 Jan; 48(1):94-100. PubMed ID: 3121169
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
25. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents.
Holden SA; Lan Y; Pardo AM; Wesolowski JS; Gillies SD
Clin Cancer Res; 2001 Sep; 7(9):2862-9. PubMed ID: 11555604
[TBL] [Abstract][Full Text] [Related]
26. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C
Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352
[TBL] [Abstract][Full Text] [Related]
27. [Enhancement of immune response by an antitumor agent, cyclophosphamide].
Nitta K; Tanaka T
Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 2):706-13. PubMed ID: 2938546
[TBL] [Abstract][Full Text] [Related]
28. [Effect of antineoplastic agents on tumor cells in vivo and in vitro (literature review)].
Merkulov MF; Shelaputina ZF; Leskova SG; Belinskiĭ VA; Talipov ASh
Farmakol Toksikol; 1971; 34(4):490-504. PubMed ID: 4334362
[No Abstract] [Full Text] [Related]
29. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors.
Hengst JC; Mokyr MB; Dray S
Cancer Res; 1981 Jun; 41(6):2163-7. PubMed ID: 7016310
[TBL] [Abstract][Full Text] [Related]
30. [Subrenal capsule assay using nude mice].
Kikuchi H; Asamura M; Gamoh M; Ohuchi H; Wakui A
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):532-41. PubMed ID: 2321981
[TBL] [Abstract][Full Text] [Related]
31. [Effect of ZGDHu-1 on proliferation and apoptosis of A549 cells in vitro and antitumor activity in vivo].
Zhou YL; Hu WX; Lü YP; Qiu LN; Wang WS; Yang ZY; Liu JD; Rao GW
Yao Xue Xue Bao; 2007 Jan; 42(1):26-34. PubMed ID: 17520803
[TBL] [Abstract][Full Text] [Related]
32. Inhibitory effect of methylation inhibitor 5-aza-2-deoxycytidine on bile duct cancer cell line in vivo and in vitro.
Tang QB; Sun HW; Zou SQ
Hepatobiliary Pancreat Dis Int; 2004 Feb; 3(1):124-8. PubMed ID: 14969854
[TBL] [Abstract][Full Text] [Related]
33. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920
[TBL] [Abstract][Full Text] [Related]
34. The role of WR-2721 in radiotherapy and/or chemotherapy.
Yuhas JM; Spellman JM; Culo F
Cancer Clin Trials; 1980; 3(3):211-6. PubMed ID: 6254681
[TBL] [Abstract][Full Text] [Related]
35. Characterization of a human ovarian carcinoma cell line: UCI 101.
Fuchtner C; Emma DA; Manetta A; Gamboa G; Bernstein R; Liao SY
Gynecol Oncol; 1993 Feb; 48(2):203-9. PubMed ID: 8428692
[TBL] [Abstract][Full Text] [Related]
36. Potentiation of concanavalin A-bound L1210 vaccine in vivo by chemotherapeutic agents.
Kataoka T; Kobayashi H; Sakurai Y
Cancer Res; 1978 May; 38(5):1202-7. PubMed ID: 639053
[No Abstract] [Full Text] [Related]
37. Growth fraction as the major determinant of multicellular tumor spheroid growth rates.
Yuhas JM; Li AP
Cancer Res; 1978 Jun; 38(6):1528-32. PubMed ID: 647668
[TBL] [Abstract][Full Text] [Related]
38. The relationship between tumour geometry and the response of tumour cells to cytotoxic drugs--an in vitro study using EMT6 multicellular spheroids.
Kwok TT; Twentyman PR
Int J Cancer; 1985 May; 35(5):675-82. PubMed ID: 3997287
[TBL] [Abstract][Full Text] [Related]
39. The response to cytotoxic drugs of EMT6 cells treated either as intact or disaggregated spheroids.
Kwok TT; Twentyman PR
Br J Cancer; 1985 Feb; 51(2):211-8. PubMed ID: 3966978
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy under cachectic conditions and the possibility of cachexia-controlled chemotherapy.
Takahashi Y; Yasumoto K; Mai M
Oncol Rep; 2005 Jul; 14(1):135-40. PubMed ID: 15944780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
